12:00 AM
Sep 18, 2006
 |  BioCentury  |  Strategy

Commercial NOtions

With lead compound naproxicinod completing its first Phase III trial in osteoarthritis ahead of schedule and having decided to develop NCX 4016 to treat Type II diabetes, NicOx S.A. is now focusing on making the transition from a research company to a fully integrated specialty pharmaceuticals business with franchises in rheumatology and cardiometabolism. The company laid out its new strategy for the first time last week.

"I haven't seen any company achieve success without selling its own drugs," Chairman and CEO Michele Garufi told analysts at NicOx's first R&D day. "For NicOx, we will achieve this by taking a three-pronged approach of developing compounds in core areas, retaining commercialization rights in specialist markets, and starting to in-license or acquire selectively compounds with strategic fit."

Part of Garufi's strategy includes learning from others' disappointing attempts to grow. Those mistakes include building large and expensive sales forces too early, being over-optimistic with sales projections and failing to build a portfolio...

Read the full 785 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >